The convergence of AI and pharmaceutics a new era of data-driven drug development

The integration of artificial intelligence (AI) into pharmaceutics is revolutionizing drug discovery, development, and delivery, offering novel data-driven approaches to optimize efficiency and precision. Traditional drug development processes are time-consuming and costly, often hindered by high attrition rates and complex regulatory requirements. AI-driven technologies, including machine learning, deep learning, and natural language processing, are reshaping the pharmaceutical landscape by expediting target identification, optimizing clinical trials, and personalizing medicine. AI enhances predictive modeling for drug behavior, accelerates repurposing efforts, and facilitates real-world evidence analysis. Moreover, AI-driven manufacturing and quality control processes improve drug production and distribution efficiency. Despite its vast potential, challenges such as data privacy, algorithmic bias, and regulatory hurdles remain significant barriers to widespread AI adoption. Addressing these concerns through ethical frameworks, transparent AI models, and standardized regulatory guidelines will ensure the responsible and equitable use of AI in pharmaceutics. This manuscript highlights the transformative role of AI in drug development, its impact on patient-centered care, and the future directions that will shape a more efficient, personalized, and data-driven pharmaceutical industry.